Family registry for hereditary amyloidosis
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study is building a registry of families with hereditary ATTR amyloidosis, a condition caused by a gene change that leads to abnormal protein buildup. By tracking your health over time, researchers hope to better understand the disease and improve care for you and your family.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must have a confirmed genetic mutation for hereditary ATTR amyloidosis.
- You must be willing to come back for regular check-ups.
- You cannot have had a heart, liver, or mechanical heart pump transplant.
- You must be able to give your own consent to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
This study looks at how a specific genetic change (Val50Met) affects people with hereditary ATTR amyloidosis. It may help doctors better understand the condition and its symptoms.
Hear when a new Amyloidosis, Hereditary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.